IonStar could upend industry standards, and quicken medical diagnosis and drug development
A new protein analysis tool developed at the University at Buffalo could vastly increase the speed and precision with which disease and drug effects are analyzed.
The groundbreaking tool, called IonStar, is the first to provide near-perfect accuracy when quantifying and comparing the abundance of proteins in the bodies of people who are healthy and ill.
Compared to industry standard MaxQuant, IonStar improved the measurement consistency of proteins in low abundance and lowered the amount of missing data in results from 17 percent to 0.1 percent, a level that has never been achieved with large samples.
The new tool could increase the quality and accuracy of medical diagnosis and quicken the pace of pharmaceutical development.
“IonStar will totally change the face of clinical and pharmaceutical research and industry, where large investigations are often critical,” says Jun Qu, PhD, lead investigator and professor in the UB School of Pharmacy and Pharmaceutical Sciences.
The research was published yesterday in the Proceedings of the National Academy of Sciences (PNAS).
Playing spot the difference
The abundance of proteins in the body that correspond with disease or pharmaceutical reactions can provide researchers with vital clues for accurately diagnosing a condition, and for developing potential therapies and evaluating drug effects.
Protein analysis tools are used to quantify and compare the abundance of proteins in groups of healthy individuals with those who are ill or treated with a drug. Changes in protein abundances, when analyzed together, often reveal novel biomarkers.
The challenge for researchers is that current tools are not efficient at analyzing large numbers of samples. One type of method, the labeling-method, uses chemical tags to label proteins. The issue: The software can only analyze up to 10 samples at a time, making it difficult for researchers to conduct typical pharmaceutical and clinical studies, says Qu.
The alternative, the label-free method, can analyze a large number of samples at once at the expense of accuracy and precision, causing researchers to waste time and resources validating falsely identified biomarkers.
IonStar increases accuracy and precision and lowers missing data by improving on sample preparation methods, alignment and feature detection designs for mass spectrometry analysis.
“For example, in clinical trials, comparing a handful of patients gets you nowhere,” says Qu. “If you can analyze a large number of patients with high-quality data, you can discover and track biomarkers much more accurately and reliably. The same is true for pharmaceutical investigations.”
Proving the concept in traumatic brain injury
Researchers used IonStar to quantify proteins in rats with traumatic brain injury, a debilitating condition that accounts for 2.2 million emergency room visits annually in the United States.
Using 100 tissue samples, IonStar identified 7,000 proteins, including 1,000 that differed in abundance, without missing data.
IonStar also measured low-abundance proteins with higher accuracy and precision than other prevalent analysis tools. This capability is critical, says Qu, because proteins that appear in smaller amounts play a more influential role in the body.
“If higher-level proteins are soldiers, then lower-level proteins are the commanders. They are the regulators that tell the higher-level proteins what to do,” says Qu.
Qu has used IonStar and similar techniques to analyze protein variation in cancer, diabetes, cardiovascular disease, neurodegeneration and retina degeneration as well.
Future work on IonStar will focus on expanding the number of samples the tool can analyze.
The Latest on: Drug development
via Google News
The Latest on: Drug development
- US FDA announces new framework to advance use of RWE to support development of drugs & biologics on December 9, 2018 at 8:30 pm
The health care system is integrating more effective ways to leverage electronic tools to gather and use vast amounts of health-related data. These tools offer new opportunities to use data collected ... […]
- Global Erythropoietin Drugs Market 2018 Distributors/Traders List, , Target Client, Brand Strategy, Marketing Channel Development and Trend to 2023 on December 8, 2018 at 11:22 pm
Erythropoietin Drugs Market greatest size in Global, Erythropoietin Drugs Market is required to High its market estimate in Upcoming Years, Erythropoietin Drugs Market Increasing Growth in Future. In ... […]
- Drug Screening Market - Technology, Trends, Development, Key Manufacturers Analysis and Forecast to 2025 on December 7, 2018 at 9:38 am
Drug screening a technical process performed for analyzing specimens such as hair, urine, oral fluids, breath, and .other samples. Drug screening aids in detection of drug or a chemical compound in th... […]
- Respiratory Drug Market Study 2018: Impressive Development to be observed in Revenue and Growth Rate across the Globe by 2025 on December 7, 2018 at 6:37 am
Stats And Reports, recently published a detailed market research study focused on the Global Respiratory Drug Market in key regions like North America, United States, Canada, Mexico, Asia-Pacific, Chi... […]
- Significant FDA Digital Health Policy Development for Prescription Drug Sponsors on December 6, 2018 at 7:43 am
As previewed by Commissioner Gottlieb several months ago (see our earlier post here), FDA published a notice in the Federal Register on November 20, 2018, to propose a new framework for “prescription ... […]
- PROVECTUS BIOPHARMACEUTICALS PROVIDES UPDATE ON MELANOMA CLINICAL DEVELOPMENT PROGRAM FOR INVESTIGATIONAL DRUG PV-10 on December 6, 2018 at 5:30 am
KNOXVILLE, TN, Dec. 06, 2018 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today provided several updates on the Company's melanoma drug development program for its lead investigational agent and ... […]
- Stimulated Development of Orphan Drug Designations for Rare Diseases and Anti-Cancer Drug Candidates Intensifies on December 6, 2018 at 4:30 am
PALM BEACH, Florida, December 6, 2018 /PRNewswire via COMTEX/ -- PALM BEACH, Florida, December 6, 2018 /PRNewswire/ -- The FDA is committed to doing what is can to stimulate the development of more pr... […]
- Hereditary Hematological Disorders - Global Drug Development Pipeline Review 2018 - ResearchAndMarkets.com on December 6, 2018 at 3:04 am
report has been added to ResearchAndMarkets.com's offering. This report provides an overview of the pipeline landscape for hereditary hematological disorders. It provides comprehensive information on ... […]
- With Gilead and rivals deep in phase 3, FDA unveils draft guidance on NASH drug development on December 4, 2018 at 5:49 am
The FDA has published draft guidance on developing NASH drugs that has implications for Gilead and the host of other companies targeting the indication. In the draft, the FDA sets out the endpoints an... […]
via Bing News